These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7874322)

  • 1. Safety of specific immunotherapy: a retrospective study.
    Luigi A; Senna G; Mezzelani P; Pappalardo G
    J Investig Allergol Clin Immunol; 1994; 4(5):250-4. PubMed ID: 7874322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonfatal systemic reactions to subcutaneous immunotherapy: a 10-year experience.
    Ragusa FV; Passalacqua G; Gambardella R; Campanari S; Barbieri MM; Scordamaglia A; Canonica GW
    J Investig Allergol Clin Immunol; 1997; 7(3):151-4. PubMed ID: 9252872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Safety analysis of dust mite allergen for diagnosis and immunotherapy of asthma and rhinitis].
    Wen T; Cai Y; Chen X; Xiang L; Wang B; Zhuang Y
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 1999; 17(5):274-6. PubMed ID: 12563856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study.
    Serrano P; Justicia JL; Sánchez C; Cimarra M; Fernández-Távora L; Orovitg A; Moreno C; Guerra F; Alvà V
    Ann Allergy Asthma Immunol; 2009 Mar; 102(3):247-52. PubMed ID: 19354072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immediate adverse reactions to immunotherapy.
    Can D; Demir E; Tanaç R; Gülen F; Yenigün A
    J Investig Allergol Clin Immunol; 2003; 13(3):177-80. PubMed ID: 14635467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adverse reactions to immunotherapy in pediatric patients].
    Avila Castañón L; Lerma-Ortiz L; Velázquez Armenta Y; del Rio Navarro BE; Sienra Monge JJ
    Rev Alerg Mex; 2003; 50(5):182-6. PubMed ID: 14631589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indications for allergen immunotherapy during pregnancy.
    Metzger WJ
    Compr Ther; 1990 Mar; 16(3):17-26. PubMed ID: 2318030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy safety: a prospective multi-centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases.
    Moreno C; Cuesta-Herranz J; Fernández-Távora L; Alvarez-Cuesta E;
    Clin Exp Allergy; 2004 Apr; 34(4):527-31. PubMed ID: 15080803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of the pediatric aspects of the WHO document and meta-analysis of immunotherapy].
    Ibáñez Sendín MD
    Allergol Immunopathol (Madr); 2000; 28(3):82-9. PubMed ID: 10867375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of sublingual grass pollen immunotherapy after anaphylaxis.
    Nichani JR; de Carpentier J
    J Laryngol Otol; 2009 Jun; 123(6):683-4. PubMed ID: 18501039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study on safty of standardized specific mite-allergen immunotherapy to children with allergic rhinitis and/or asthma].
    Wu Y; Long Z; Huang Y; Huang X
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2011 Jul; 25(14):641-4. PubMed ID: 22032122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of specific immunotherapy with standardized allergenic extracts adsorbed on aluminium hydroxide.
    Wüthrich B; Gumowski PL; Fäh J; Hürlimann A; Deluze C; André C; Fadel R; Carat F
    J Investig Allergol Clin Immunol; 2001; 11(3):149-56. PubMed ID: 11831445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rhinitis and asthma co-morbidity in respiratory allergy due to house dust mite: results of an observational open controlled parallel group study in real-life setting.
    Marogna M; Spadolini I; Massolo A
    Eur Ann Allergy Clin Immunol; 2005 Apr; 37(4):135-42. PubMed ID: 15916014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-fatal systemic reactions to subcutaneous immunotherapy: a 20-year experience comparison of two 10-year periods.
    Ragusa VF; Massolo A
    Eur Ann Allergy Clin Immunol; 2004 Feb; 36(2):52-5. PubMed ID: 15061395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Preventive immunotherapy].
    Boquete M; Carballada F; Expósito F; González A
    Allergol Immunopathol (Madr); 2000; 28(3):89-93. PubMed ID: 10867376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy units: a follow-up study.
    Machín IS; Robaina JCG ; Bonnet C; de Blas C; Fernández-Caldas E; Triviño MS; de la Morin FT
    J Investig Allergol Clin Immunol; 2001; 11(3):167-71. PubMed ID: 11831448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hyposensitization treatment of allergic diseases].
    Wüthrich B
    Schweiz Rundsch Med Prax; 1993 May; 82(18):529-33. PubMed ID: 8497762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety of allergen immunotherapy (IT) in Turkey.
    Dursun AB; Sin BA; Oner F; Misirligil Z
    J Investig Allergol Clin Immunol; 2006; 16(2):123-8. PubMed ID: 16689186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for adverse systemic reactions occurring during immunotherapy with standardized Dermatophagoides farinae extracts.
    Ohashi Y; Nakai Y; Tanaka A; Kakinoki Y; Washio Y; Ohno Y; Yamada K; Nasako Y
    Acta Otolaryngol Suppl; 1998; 538():113-7. PubMed ID: 9879410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerance of immunotherapy with a standardized extract of Alternaria tenuis in patients with rhinitis and bronchial asthma.
    Tabar AI; Lizaso MT; García BE; Echechipía S; Olaguibel JM; Rodríguez A
    J Investig Allergol Clin Immunol; 2000; 10(6):327-33. PubMed ID: 11206932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.